FEIOF yields 9.51% · JNJ yields 2.14%● Live data
📍 FEIOF pulled ahead of the other in Year 1
Combined, FEIOF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FEIOF + JNJ for your $10,000?
Feintool International Holding AG, together with its subsidiaries, provides fineblanked, formed steel components, and punched electro sheet metal products in Switzerland, rest of Europe, Germany, the United States, Japan, and China. It operates through two segments, System Parts and Fineblanking Technology. The System Parts segment develops, produces, and sells high-precision system components and assemblies using fineblanking and forming technology, as well as electronic sheet stamping; and sells production-specific tools to third-party customers. The Fineblanking Technology segment engages in the development, manufacture, and sale of presses, tools, peripheral systems, and various related services. It provides its products for use in automobile industry, such as engine, chassis, transmission, safety systems, peripheral drives, and seat mechanisms applications, as well as for application in mechanical engineering, power generation, electric motors and drives, tools and household, and medical technology. The company was founded in 1959 and is headquartered in Lyss, Switzerland. Feintool International Holding AG is a subsidiary of Artemis Beteiligungen I AG.
Full FEIOF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.